Evidence map›Paper›PMID 37170749›Full record

ArticleThe Journal of international medical research2023

Serial measurements of lymphocytes, D-dimer, LDH, and CRP do not improve the ability to predict COVID-19 adverse outcomes.

Jorge Pulido-Arenas, Daniela Saa-González, Oscar M Muñoz, Alejandra Cañas-Arboleda

Open access · goldAbstract read
In one paragraph

Article in The Journal of international medical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Jorge Pulido-ArenasSchool of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.ORCID 0000-0001-8866-3033
Daniela Saa-GonzálezSchool of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.
Oscar M MuñozSchool of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.ORCID 0000-0001-5401-0018
Alejandra Cañas-ArboledaSchool of Medicine, Pontificia Universidad Javeriana, Bogotá, Colombia.ORCID 0000-0002-0104-4107
Pontificia Universidad Javeriana · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveWe evaluated the discriminatory ability of variations in lymphocyte, D-dimer, C-reactive protein (CRP), and lactate dehydrogenase (LDH) serum levels at 48 to 72 hours of hospitalization compared with baseline measurements to predict unfavorable clinical outcomes in patients with COVID-19.

methodsWe analyzed diagnostic test results based on a retrospective cohort to determine the ability of variations (gradients or ratios) in patients' lymphocyte, D-dimer, CRP, and LDH serum levels taken 48 to 72 hours after hospital admission to predict adverse outcomes such as death, mechanical ventilation, or intensive care unit (ICU) admission developing.

resultsAmong 810 patients (56.1% men, age 61.6 ± 16.2 years), 37.5% had at least one adverse outcome; 28.2% required ICU admission, 26.5% required mechanical ventilation, and 19.4% died during hospitalization. In comparing baseline measurements with measurements at 48 to 72 hours, D-dimer, lymphocyte delta, LDH, and CRP had similar discriminatory ability (area under the receiver operating characteristic curve [AUC] 0.57 vs. 0.56, 0.53 vs. 0.57, 0.64 vs. 0.66, and 0.62 vs. 0.65, respectively).

conclusionsMeasuring serum risk markers upon hospital admission can be used to evaluate risk of adverse outcomes in hospitalized patients with COVID-19. Repeating these measurements at 48 to 72 hours does not improve discriminatory ability.

Indexed as

COVID-19AgedBiomarkersC-Reactive ProteinFemaleFibrin Fibrinogen Degradation ProductsHumansLymphocytesMaleMiddle AgedRetrospective StudiesBiomarkersC-Reactive ProteinFibrin Fibrinogen Degradation Productsfibrin fragment Dadverse outcomeCOVID-19mortalitypredictionretrospective cohortSerum biomarker

Identifiers

PMID37170749
PMCPMC10184212
OpenAlexW4376224796

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.